Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Roche's Tiragolumab?
Tiragolumab is a monoclonal antibody commercialized by Roche, with a leading Phase III program in Esophageal Squamous Cell Carcinoma (ESCC)....
Tiragolumab by Genentech USA for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase I for Metastatic Renal Cell Carcinoma. According to...
Tiragolumab by Genentech USA for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Esophageal Squamous Cell Carcinoma (ESCC). According...
Tiragolumab by Genentech USA for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Tiragolumab by Genentech USA for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Metastatic Hepatocellular Carcinoma (HCC). According to...
Tiragolumab by Genentech USA for Solid Tumor: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Solid Tumor. According to GlobalData, Phase...